The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study.
 
Sara Valpione
No Relationships to Disclose
 
Matteo S. Carlino
No Relationships to Disclose
 
Joanna Mangana
No Relationships to Disclose
 
Meghan Mooradian
No Relationships to Disclose
 
Grant A. McArthur
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Dirk Schadendorf
Honoraria - Agenus; Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Grunenthal; Immunocore; Incyte; LEO Pharma; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche/Genentech; Sysmex
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Grunenthal; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Roche/Genentech; Sysmex
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Incyte; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; Merck Serono; Novartis; Roche/Genentech
 
Axel Hauschild
Honoraria - Amgen; Bristol-Myers Squibb; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Novartis; OncoSec; Philogen; Provectus; Regeneron; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar Therapeutics, Philogen, Provectus, Regeneron; Novartis; OncoSec; Roche
Research Funding - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; Merck Serono; Merck Sharp & Dohme; Novartis; Roche
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar Therapeutics, Philogen, Provectus, Regeneron; Novartis; OncoSec; Roche
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Merck; Roche
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; MERCK; Novartis; Pierre Fabre; Roche/Genentech
Travel, Accommodations, Expenses - Merck Sharp & Dohme; Roche/Genentech
 
Ana M. Arance
No Relationships to Disclose
 
Paolo Antonio Ascierto
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Roche/Genentech (Inst)
 
Michele Maio
Consulting or Advisory Role - Bristol-Myers Squibb; Roche
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst)
 
Francesco De Rosa
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
James M. G. Larkin
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Pfizer; Roche
Research Funding - Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
 
John J. Park
No Relationships to Disclose
 
Simone M. Goldinger
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Roche
 
Keith Flaherty
Stock and Other Ownership Interests - Clovis Oncology; Loxo
Consulting or Advisory Role - Adaptimmune; Aeglea Biotherapeutics; Amgen; Asana Biosciences; Bristol-Myers Squibb; Clovis Oncology; Genentech; Lilly; Loxo; Merck; miRNA Therapeutics; Novartis; Oncoceutics; Roche; Sanofi; Tioma Therapeutics
Research Funding - Novartis; Sanofi
 
Wen Xu
No Relationships to Disclose
 
Elisabeth Livingstone
Honoraria - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Medac; Merck Serono; MSD; Novartis; Roche
Consulting or Advisory Role - Amgen; Roche
Speakers' Bureau - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Roche
Travel, Accommodations, Expenses - Amgen; Boehringer Ingelheim; MSD; Novartis
 
Michael Weichenthal
Honoraria - Bristol-Myers Squibb; Medac; Merck Sharp & Dohme; Novartis; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Medac; Merck Sharp & Dohme; Novartis; Roche
Research Funding - Bristol-Myers Squibb (Inst); Johnson & Johnson (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Amgen; Merck Sharp & Dohme
 
Paul Lorigan
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Novartis
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme